These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 28880446)

  • 1. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.
    Srinivas NR
    Aliment Pharmacol Ther; 2017 Oct; 46(7):706-707. PubMed ID: 28880446
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury-authors' reply.
    Nuki Y; Esaki M
    Aliment Pharmacol Ther; 2017 Oct; 46(7):708. PubMed ID: 28880441
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
    Nuki Y; Umeno J; Washio E; Maehata Y; Hirano A; Miyazaki M; Kobayashi H; Kitazono T; Matsumoto T; Esaki M
    Aliment Pharmacol Ther; 2017 Aug; 46(3):331-336. PubMed ID: 28481007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract]   [Full Text] [Related]  

  • 8. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
    Ariizumi K; Ohara S; Koike T; Inomata Y; Iijima K; Sekine H; Noguchi M; Sugiyama K; Eda Y; Kayaba S; Kawamura M; Shimosegawa T
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1428-34. PubMed ID: 16911688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
    Sugimoto M; Furuta T; Nakmura A; Shirai N
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
    Yamano HO; Matsushita HO; Yanagiwara S
    J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.